Shares of REGENXBIO (RGNX) have risen by roughly 50% since I first presented the company as an early stage gene therapy pioneer worthy of consideration. In late March I recommended investors buy shares on weakness and just a couple months later there was a decent dip to take advantage of.
Keys to the investing thesis included the following:
